Novo Nordisk ousts CEO after falling behind in weight loss market

I believe that if they had more competitive pricing on their products here in the states especially, this would not be in the news right now. Just my 2 cents.
 
Novo's shares have plunged since hitting a record-high in June last year as competition, particularly from U.S. rival Eli Lilly (LLY.N), makes inroads into its market share and as its pipeline of new drugs has failed to impress investors.

On the surface, it does seem like Novo Nordisk is afraid to compete on price with Zepbound, even though doctors are recommending Zepbound over Wegovy.
 

Trending content

Latest posts

Forum statistics

Threads
3,156
Messages
52,553
Members
6,590
Latest member
Kmoney29
Back
Top Bottom